Prostate Cancer Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Silenseed, Lantheus, Pantarhei

The Prostate Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Prostate Cancer Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Prostate Cancer Market.

Some of the key takeaways from the Prostate Cancer Pipeline Report:

• Companies across the globe are diligently working toward developing novel Prostate Cancer treatment therapies with a considerable amount of success over the years. 
• Prostate Cancer companies working in the treatment market are Silenseed LTD, Lantheus, Pantarhei Oncology, ORCA Therapeutics, Regeneron Pharmaceuticals, Astellas Pharma Inc, Antev, Zenith Epigenetics, POINT Biopharma, Tavanta Therapeutics, Exelixis, Pfizer, Janssen Pharmaceutical, Merck & Co, AstraZeneca, Veru Healthcare, Matrix Biomed, Zenith Epigenetics, RhoVac, Gilead Sciences, Promontory Therapeutics, ESSA Pharma, Hookipa Biotech, BioNTech SE, Amgen, Janux Therapeutics, ORIC Pharmaceuticals, and others, are developing therapies for the Prostate Cancer treatment 

• Emerging Prostate Cancer therapies in the different phases of clinical trials are- PT-LODER, LNTH-1558, Zona pellucida Immunotherapy, ORCA-010, REGN5678, Enfortumab vedotin, Teverelix-TFA, ZEN 3694, PNT2002, TAVT-45, Cabozantinib, Talazoparib, Niraparib, Pembrolizumab, Capivasertib, VERU-111, MBM-02, ZEN 3694, Onilcamotide, IMMU-132, PT-112, EPI-7386, HB-302, BNT112, AMG 509, JANX007, ORIC-944, and others are expected to have a significant impact on the Prostate Cancer market in the coming years.   
• In February 2023, The investigational new drug application for the ongoing Phase II clinical trial (the “TATCIST” trial) evaluating 225Ac-PSMA I&T, a small molecule targeting prostate-specific membrane antigen (“PSMA”) expressed on prostate cancers, has been acquired by Fusion Pharmaceuticals from RadioMedix, Inc. The alpha-emitting radiopharmaceutical being assessed in the TATCIST study will be known as FPI-2265 after the closing
• In February 2023, CSPC Megalith Biopharmaceutical Co., Ltd., a division of CSPC Pharmaceutical Group Limited, and Corbus Pharmaceuticals have engaged into an exclusive licencing agreement for the development and marketing of CRB-701 (SYS6002), a brand-new antibody drug conjugate (ADC) that is in the clinical stage and targets Nectin-4. The deal includes exclusive commercialization rights for CRB-701 in the US, Canada, UK, Australia, the European Union (including the European Free Trade Area), and other countries. All rights to SYS6002 in the remaining international markets will stay with CSPC. The focus of clinical development is urothelial cancer and other solid tumours that are Nectin-4 positive, which may include lung, breast, and prostate cancer.
• In February 2023, After at least one prior line of chemotherapy for locally advanced or metastatic prostate cancer, BioXcel Therapeutics, Inc. reported full data from its Phase IIa trial of BXCL701, the company’s investigational oral innate immune activator, in combination with KEYTRUDA (pembrolizumab) in small cell neuroendocrine (SCNC) variant metastatic castration-resistant prostate cancer (mCRPC) patients. The results will be presented on February 16, 2023, at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) Symposium in a quick abstract presentation and a poster presentation.
• In January 2023, Onxeo S.A. provided an update on the AsiDNA, a first-in-class therapeutic candidate, clinical development programme. Next Oncology San Antonio, Onxeo’s first clinical study location in the US, is now operational. In this phase I/II multicenter basket trial, patients with recurrent ovarian, breast, and metastatic castration-resistant prostate cancer (mCRPC) who have progressed on prior PARP inhibitor therapy will be evaluated for safety and early activity of AsiDNA in combination with olaparib.
• In February 2022, Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today the administration of ZEN-3694 (a BET inhibitor) in combination with Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor OPDIVO and YERVOY in a solid tumour cancer trial sponsored by the National Cancer Institute (NCI), a division of the National Institutes of Health.
• In September 2021, In a phase 2b randomised trial comparing ZEN003694 in combination with Enzalutamide to Enzalutamide monotherapy in patients with metastatic castration-resistant prostate cancer, Zenith Epigenetics, Astellas Pharma Inc., and Newsoara Biopharma Co., Ltd.

Prostate Cancer Overview

When cells in the prostate gland begin to grow out of control, prostate cancer develops. Only men have the prostate gland in their bodies. Some of the fluid that is a component of semen is created. DNA alterations are the primary cause of prostate cancer. DNA mutations cause these modifications to take place.

Get a Free Sample PDF Report to know more about Prostate Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/prostate-cancer-pipeline-insight

Emerging Prostate Cancer Drugs Under Different Phases of Clinical Development Include:

• PT-LODER: Silenseed LTD
• LNTH-1558: Lantheus
• Zona pellucida Immunotherapy: Pantarhei Oncology
• ORCA-010: ORCA Therapeutics
• REGN5678: Regeneron Pharmaceuticals
• Enfortumab vedotin: Astellas Pharma Inc
• Teverelix-TFA: Antev
• ZEN 3694: Zenith Epigenetics
• PNT2002: POINT Biopharma
• TAVT-45: Tavanta Therapeutics
• Cabozantinib: Exelixis
• Talazoparib: Pfizer
• Niraparib: Janssen Pharmaceutical
• Pembrolizumab: Merck & Co
• Capivasertib: AstraZeneca
• VERU-111: Veru Healthcare
• MBM-02: Matrix Biomed
• Onilcamotide: RhoVac
• IMMU-132: Gilead Sciences
• PT-112: Promontory Therapeutics
• EPI-7386: ESSA Pharma
• HB-302: Hookipa Biotech
• BNT112: BioNTech SE
• AMG 509: Amgen
• JANX007: Janux Therapeutics
• ORIC-944: ORIC Pharmaceuticals
• ODM-208: Orion

Prostate Cancer Route of Administration

Prostate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Prostate Cancer Molecule Type

Prostate Cancer Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Prostate Cancer Pipeline Therapeutics Assessment

• Prostate Cancer Assessment by Product Type
• Prostate Cancer By Stage and Product Type
• Prostate Cancer Assessment by Route of Administration
• Prostate Cancer By Stage and Route of Administration
• Prostate Cancer Assessment by Molecule Type
• Prostate Cancer by Stage and Molecule Type

DelveInsight’s Prostate Cancer Report covers around 200+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Prostate Cancer product details are provided in the report. Download the Prostate Cancer pipeline report to learn more about the emerging Prostate Cancer therapies

Some of the key companies in the Prostate Cancer Therapeutics Market include:

Key companies developing therapies for Prostate Cancer are – Merck & Co, Pfizer, Orion, Zenith Epigenetics, ESSA Pharma, RhoVac, AstraZeneca, Advaxis, Inc., Tracon Pharmaceuticals Inc., Bristol-Myers Squibb, Laekna Limited, Bracco Diagnostics, Inc, Arvinas Inc, Epizyme, Regeneron Pharmaceuticals, Veru Inc., Eli Lilly and Company, Exelixis, Luye Pharma Group, Amgen, Innocrin Pharmaceutical, Bayer, Nymox Pharmaceutical, Matrix Biomed, Tavanta Therapeutics, Fortis Therapeutics, Inc., Janssen Research & Development, LLC, Clarity Pharmaceuticals, Leap Therapeutics, Hinova pharmaceuticals, Vaccitech, Cardiff Oncology, Suzhou Kintor Pharmaceuticals, Teneobio, Inc., Janux Therapeutics, Fusion Pharmaceuticals, Corbus Pharmaceuticals, BioXcel Therapeutics, Onxeo S.A, Ayala Pharmaceuticals, HOOKIPA Pharma, Nuvation Bio, Ambrx, enGene, Jemincare, CellVax Therapeutics, POINT Biopharma, Oncternal Therapeutics, Immunic AG, BioNTech SE,  and others

Prostate Cancer Pipeline Analysis:

The Prostate Cancer pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Prostate Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Prostate Cancer Treatment.
• Prostate Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Prostate Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Prostate Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Prostate Cancer drugs and therapies

Prostate Cancer Pipeline Market Drivers

• Rising aging population and high prevalence rate of Prostate Cancer, innovation in drugs and developments in genomics and proteomics, presence of advanced diagnosis techniques are some of the important factors that are fueling the Prostate Cancer Market.

Prostate Cancer Pipeline Market Barriers

• However, problem of over diagnosis, high cost of Prostate Cancer drugs, side-effects associated with treatment and other factors are creating obstacles in the Prostate Cancer Market growth.

Scope of Prostate Cancer Pipeline Drug Insight    

• Coverage: Global
• Key Prostate Cancer Companies: Silenseed LTD, Lantheus, Pantarhei Oncology, ORCA Therapeutics, Regeneron Pharmaceuticals, Astellas Pharma Inc, Antev, Zenith Epigenetics, POINT Biopharma, Tavanta Therapeutics, Exelixis, Pfizer, Janssen Pharmaceutical, Merck & Co, AstraZeneca, Veru Healthcare, Matrix Biomed, Zenith Epigenetics, RhoVac, Gilead Sciences, Promontory Therapeutics, ESSA Pharma, Hookipa Biotech, BioNTech SE, Amgen, Janux Therapeutics, ORIC Pharmaceuticals, and others
• Key Prostate Cancer Therapies: PT-LODER, LNTH-1558, Zona pellucida Immunotherapy, ORCA-010, REGN5678, Enfortumab vedotin, Teverelix-TFA, ZEN 3694, PNT2002, TAVT-45, Cabozantinib, Talazoparib, Niraparib, Pembrolizumab, Capivasertib, VERU-111, MBM-02, ZEN 3694, Onilcamotide, IMMU-132, PT-112, EPI-7386, HB-302, BNT112, AMG 509, JANX007, ORIC-944, and others
• Prostate Cancer Therapeutic Assessment: Prostate Cancer current marketed and Prostate Cancer emerging therapies
• Prostate Cancer Market Dynamics: Prostate Cancer market drivers and Prostate Cancer market barriers 

Request for Sample PDF Report for Prostate Cancer Pipeline Assessment and clinical trials

Table of Contents 

1. Prostate Cancer Report Introduction

2. Prostate Cancer Executive Summary

3. Prostate Cancer Overview

4. Prostate Cancer- Analytical Perspective In-depth Commercial Assessment

5. Prostate Cancer Pipeline Therapeutics

6. Prostate Cancer Late Stage Products (Phase II/III)

7. Prostate Cancer Mid Stage Products (Phase II)

8. Prostate Cancer Early Stage Products (Phase I)

9. Prostate Cancer Preclinical Stage Products

10. Prostate Cancer Therapeutics Assessment

11. Prostate Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Prostate Cancer Key Companies

14. Prostate Cancer Key Products

15. Prostate Cancer Unmet Needs

16 . Prostate Cancer Market Drivers and Barriers

17. Prostate Cancer Future Perspectives and Conclusion

18. Prostate Cancer Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services